Elasticity of adenomyosis is increased after GnRHa therapy and is associated with spontaneous pregnancy in infertile patents.

Xie M, Yu H, Zhang X, Wang W, Ren Y

Journal of gynecology obstetrics and human reproduction5 May 2019Cited by 18 (Europe PMC)

PMID31067498DOI10.1016/j.jogoh.2019.05.003PepBankPUB-31067498

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In infertile patients with adenomyosis receiving triptorelin plus add-back therapy, twelve became pregnant during follow-up.
In plain wordsAmong infertile patients with adenomyosis receiving triptorelin plus add-back therapy, twelve became pregnant during follow-up.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePregnancy during follow-up
Study
n = 45
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Patients pregnant during follow-up
12 patients
6-month follow-up, 45 patients analysed
Source sentences
Summary
Twelve cases (group 1) were pregnancy during the follow-up and the other thirty-three cases (group 2) failed their attempts.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective observational study included patients who were diagnosed as adenomyosis by conventional transvaginal ultrasound and infertility.
Summary · context
The sonographic characters of elastography, the degree of dysmenorrhea and the values of serum CA125 before and following GnRHa (Triptorelin 3.75 mg were administered every 28 days) plus add-back therapy were reviewed and analyzed.
Summary · context
45 patients who completed the 6 months follow-up were included in the analysis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3106749801
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In infertile patients with adenomyosis, dysmenorrhea scores decreased after triptorelin plus add-back therapy versus before therapy.
In plain wordsIn patients with adenomyosis, pain scores decreased after triptorelin plus add-back therapy compared with before therapy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseDysmenorrhea numerical rating scale
Study
n = 45
Comparator
Before therapy
Outcome group
Pain · Reproductive and sexual health
Source sentences
Summary
The numerical rating scale and CA125 of all the cases were both significantly reduced 6 months after therapy.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective observational study included patients who were diagnosed as adenomyosis by conventional transvaginal ultrasound and infertility.
Summary · context
The sonographic characters of elastography, the degree of dysmenorrhea and the values of serum CA125 before and following GnRHa (Triptorelin 3.75 mg were administered every 28 days) plus add-back therapy were reviewed and analyzed.
Summary · context
45 patients who completed the 6 months follow-up were included in the analysis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3106749802
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In infertile patients with adenomyosis, serum CA125 decreased after triptorelin plus add-back therapy versus before therapy.
In plain wordsIn patients with adenomyosis, CA125 decreased after triptorelin plus add-back therapy compared with before therapy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum CA125
Study
n = 45
Comparator
Before therapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
The numerical rating scale and CA125 of all the cases were both significantly reduced 6 months after therapy.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective observational study included patients who were diagnosed as adenomyosis by conventional transvaginal ultrasound and infertility.
Summary · context
The sonographic characters of elastography, the degree of dysmenorrhea and the values of serum CA125 before and following GnRHa (Triptorelin 3.75 mg were administered every 28 days) plus add-back therapy were reviewed and analyzed.
Summary · context
45 patients who completed the 6 months follow-up were included in the analysis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3106749803
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In patients who did not become pregnant, uterine elasticity scores did not significantly change after triptorelin plus add-back therapy.
In plain wordsIn patients without pregnancy, uterine elasticity scores did not significantly change after triptorelin plus add-back therapy compared with before therapy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeUterine elasticity in patients who did not become pregnant
Study
n = 33
Comparator
Before therapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Mean uterine elasticity score
2.2 score
group 2 after therapy (SD 0.5)
Mean uterine elasticity score
2.5 score
group 2 before therapy (SD 0.6)
Source sentences
Summary
In group 2, the mean elasticity score did not change for the uterine after therapy than before (2.2 ± 0.5 vs 2.5 ± 0.6, p = 0.77).
4 context sentences(design, population, supporting numbers)
Summary · context
Twelve cases (group 1) were pregnancy during the follow-up and the other thirty-three cases (group 2) failed their attempts.
Summary · context
A prospective observational study included patients who were diagnosed as adenomyosis by conventional transvaginal ultrasound and infertility.
Summary · context
The sonographic characters of elastography, the degree of dysmenorrhea and the values of serum CA125 before and following GnRHa (Triptorelin 3.75 mg were administered every 28 days) plus add-back therapy were reviewed and analyzed.
Summary · context
45 patients who completed the 6 months follow-up were included in the analysis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3106749806
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In patients who became pregnant, uterine elasticity scores increased after triptorelin plus add-back therapy versus before therapy.
In plain wordsIn patients who became pregnant, uterine elasticity scores increased after triptorelin plus add-back therapy compared with before therapy.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseUterine elasticity in patients who became pregnant
Study
n = 12
Comparator
Before therapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Mean uterine elasticity score
3.6 score
group 1 after therapy (SD 0.3)
Mean uterine elasticity score
2.3 score
group 1 before therapy (SD 0.5)
Source sentences
Summary
In group 1, the mean elasticity score was significantly higher for the uterine after therapy than before (3.6 ± 0.3 vs 2.3 ± 0.5, p = 0.004).
4 context sentences(design, population, supporting numbers)
Summary · context
Twelve cases (group 1) were pregnancy during the follow-up and the other thirty-three cases (group 2) failed their attempts.
Summary · context
A prospective observational study included patients who were diagnosed as adenomyosis by conventional transvaginal ultrasound and infertility.
Summary · context
The sonographic characters of elastography, the degree of dysmenorrhea and the values of serum CA125 before and following GnRHa (Triptorelin 3.75 mg were administered every 28 days) plus add-back therapy were reviewed and analyzed.
Summary · context
45 patients who completed the 6 months follow-up were included in the analysis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3106749805
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In infertile patients with adenomyosis receiving triptorelin plus add-back therapy, all enlarged uteri decreased to accessible normal size.
In plain wordsIn patients with adenomyosis receiving triptorelin plus add-back therapy, enlarged uteri decreased to normal size.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUterine size
Study
n: not reported in source
Comparator
Before therapy
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
All of enlarged uterus decreased to accessible normal size.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective observational study included patients who were diagnosed as adenomyosis by conventional transvaginal ultrasound and infertility.
Summary · context
The sonographic characters of elastography, the degree of dysmenorrhea and the values of serum CA125 before and following GnRHa (Triptorelin 3.75 mg were administered every 28 days) plus add-back therapy were reviewed and analyzed.
Summary · context
45 patients who completed the 6 months follow-up were included in the analysis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3106749804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.